William Blair Investment Management LLC Cuts Position in ANI Pharmaceuticals, Inc. $ANIP

William Blair Investment Management LLC lowered its holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 7.1% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 490,536 shares of the specialty pharmaceutical company’s stock after selling 37,740 shares during the quarter. William Blair Investment Management LLC’s holdings in ANI Pharmaceuticals were worth $32,007,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also made changes to their positions in ANIP. Advisors Asset Management Inc. purchased a new position in shares of ANI Pharmaceuticals in the 1st quarter valued at about $28,000. National Bank of Canada FI acquired a new position in ANI Pharmaceuticals during the first quarter worth about $79,000. GAMMA Investing LLC increased its holdings in ANI Pharmaceuticals by 163.8% in the first quarter. GAMMA Investing LLC now owns 1,419 shares of the specialty pharmaceutical company’s stock valued at $95,000 after buying an additional 881 shares in the last quarter. Mesirow Financial Investment Management Inc. acquired a new stake in shares of ANI Pharmaceuticals during the 1st quarter valued at approximately $206,000. Finally, KLP Kapitalforvaltning AS boosted its stake in shares of ANI Pharmaceuticals by 23.3% during the 2nd quarter. KLP Kapitalforvaltning AS now owns 3,700 shares of the specialty pharmaceutical company’s stock worth $241,000 after acquiring an additional 700 shares in the last quarter. 76.05% of the stock is owned by institutional investors and hedge funds.

ANI Pharmaceuticals Stock Up 3.1%

Shares of NASDAQ:ANIP opened at $94.79 on Friday. The company has a market capitalization of $2.06 billion, a P/E ratio of -123.10 and a beta of 0.58. The stock’s fifty day simple moving average is $92.70 and its 200-day simple moving average is $74.84. ANI Pharmaceuticals, Inc. has a 52-week low of $52.50 and a 52-week high of $99.50. The company has a quick ratio of 1.96, a current ratio of 2.54 and a debt-to-equity ratio of 1.39.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its earnings results on Thursday, June 8th. The specialty pharmaceutical company reported ($0.12) earnings per share (EPS) for the quarter. ANI Pharmaceuticals had a negative net margin of 1.37% and a positive return on equity of 25.03%. The firm had revenue of $64.48 million during the quarter. As a group, equities research analysts forecast that ANI Pharmaceuticals, Inc. will post 3.86 earnings per share for the current fiscal year.

Analysts Set New Price Targets

ANIP has been the subject of several research analyst reports. Zacks Research raised ANI Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Thursday, August 21st. Guggenheim upped their target price on ANI Pharmaceuticals from $86.00 to $114.00 and gave the company a “buy” rating in a report on Monday, September 8th. Wall Street Zen raised ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 16th. Truist Financial increased their price objective on shares of ANI Pharmaceuticals from $77.00 to $90.00 and gave the company a “hold” rating in a research note on Thursday, October 9th. Finally, Weiss Ratings downgraded shares of ANI Pharmaceuticals from a “hold (c-)” rating to a “sell (d+)” rating in a report on Wednesday, October 8th. Two investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $99.14.

Insider Activity

In other news, COO Muthusamy Shanmugam sold 52,988 shares of ANI Pharmaceuticals stock in a transaction on Thursday, August 21st. The stock was sold at an average price of $90.44, for a total value of $4,792,234.72. Following the completion of the sale, the chief operating officer owned 431,920 shares of the company’s stock, valued at $39,062,844.80. The trade was a 10.93% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Meredith Cook sold 400 shares of the company’s stock in a transaction on Monday, October 13th. The shares were sold at an average price of $90.09, for a total value of $36,036.00. Following the completion of the transaction, the vice president owned 75,674 shares of the company’s stock, valued at $6,817,470.66. The trade was a 0.53% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 413,830 shares of company stock valued at $36,505,378 in the last 90 days. Insiders own 11.10% of the company’s stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.